🇺🇸 Ketamine + Lidocaine in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Adrenal Insufficiency — 1 report (10%)
2. Aerophobia — 1 report (10%)
3. Anaemia Of Chronic Disease — 1 report (10%)
4. Application Site Vesicles — 1 report (10%)
5. Asthenia — 1 report (10%)
6. Basal Cell Carcinoma — 1 report (10%)
7. Bone Marrow Failure — 1 report (10%)
8. Constipation — 1 report (10%)
9. Diarrhoea — 1 report (10%)
10. Documented Hypersensitivity To Administered Product — 1 report (10%)

Source database →

Frequently asked questions

Is Ketamine + Lidocaine approved in United States?

Ketamine + Lidocaine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ketamine + Lidocaine in United States?

State University of New York at Buffalo is the originator. The local marketing authorisation holder may differ — check the official source linked above.